- Total revenue in the second quarter of fiscal year 2019 up to $648,265
- Revenue growth is due to an increase in hemp and CBD product sales, as well as heightened subscriptions totals
- As the hemp and CBD markets continue to expand, ChineseInvestors.com is expecting even stronger performance through the second half of FY2019
ChineseInvestors.com Inc. (OTCQB: CIIX), developer of a proprietary financial news media and content platform providing information to the global Chinese-speaking community, recently announced its financial results for the second quarter of fiscal year 2019, pinpointing a number of important accomplishments. A revenue increase of more than 50 percent year-over-year is one of the key milestones presented in January 22, 2019, news release (http://ibn.fm/U36su).
One of the biggest drivers for the excellent financial performance was the increase in hemp and CBD sales revenue. Year-over-year, hemp and CBD sales revenues were up by eight percent.
Subscription revenues for the premier financial information website targeting Chinese-speaking investors also increased by 40 percent year-over-year.
These two primary factors driving the growth of ChineseInvestors.com contributed to revenues of $648,265 for the second quarter of fiscal year 2019. For the six months ended November 30, total revenue reached $1,360,625, in comparison to $882,951 for the same period of 2017.
These results indicate that CIIX’s investment in existing markets, as well as new opportunities, has paid off, as noted by ChineseInvestors.com CEO Warren Wang. ChineseInvestors.com’s investors are positioned to benefit from the growth drivers that have already been implemented, including the launch of CBD Biotechnology Co. Ltd.’s Hemp Wine.
CBD Biotechnology Co Ltd. is a wholly owned ChineseInvestors.com foreign enterprise. Hemp Wine was launched mid-January 2019. The product is a self-branded type of rice wine created to specifically target the global Chinese wellness market. The proprietary blend includes hemp, ginseng and other carefully chosen ingredients (http://ibn.fm/omBYw).
In 2018, CBD Biotechnology Company put many drivers in place to fuel future growth, CFO Alex Hamilton said. The progress registered in China is very exciting, and the company will continue to develop innovative hemp and CBD products in the future, he concluded.
CBD Biotechnology also focuses its activities on the sales of hemp-infused skin care products via both digital and traditional distribution channels. The expansion of the consumer line and the prominence of hemp/CBD products are expected to fuel further positive developments in 2019, on top of the subscription-based services offered by ChineseInvestors.com.
According to Wang, ChineseInvestors.com is looking forward to an even stronger performance in the upcoming months. “As we leverage the momentum already in place, we look forward to having an even stronger second half for FY 2019,” he noted in a news release.
The story of ChineseInvestors.com started in 1999 when the company was set up for the purpose of providing real-time market commentary, analysis and education-related services in Chinese via an online platform. In addition, the company offers advertising and PR support services, direct and online sales of hemp-based products and other related health products.
For more information, visit the company’s website at www.ChineseInvestors.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
